Radiotherapy With Extreme Hypofractionation in Patients With Breast Cancer in Brazil: a Retrospective Cohort Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05776147

Acronym

RADIANT

Enrollment

461

Registered

2023-03-20

Start date

2023-11-09

Completion date

2024-09-02

Last updated

2026-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Radiotherapy Side Effect

Brief summary

The radiotherapy scheme with extreme hypofractionation has gained space in clinical practice and, therefore, it is necessary to analyze the Brazilian national experience in selected patients with breast cancer, with the aim of evaluating the oncological outcomes and toxicities with the use of this treatment protocol.

Detailed description

All patients diagnosed with breast cancer who meet the eligibility criteria at participating centers will be included. Data will be collected from medical records at selected centers. Data collection will start from the location activation date. Data from up to 500 patients are expected to be collected at centers across Brazil. Patients recruited for this study will be identified at participating centers. Data on clinical, demographic and socioeconomic variables will be collected, as well as data on treatments performed and outcomes. The patient data sources will be the patients' medical records. Patients will continue to receive treatment and clinical evaluations for their illness as determined by their medical team, in accordance with the standards of care and usual clinical practice at each center. No intervention is proposed in this study.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Inclusion criteria

* Women over 18 years old; * Diagnosis of breast cancer of any molecular subtype; * Undergoing extreme hypofractionated radiotherapy (5 x 5.2Gy) postoperatively; * Treated from December/2019 onward; * With clinical and treatment data available in medical records.

Exclusion criteria

* The protocol does not provide

Design outcomes

Primary

Measure	Time frame	Description
Locoregional recurrence	18 months	To evaluate the effectiveness of the extreme hypofractionation scheme, in 5 fractions of 5.2 Gy, in women with breast cancer

Countries

Brazil

Contacts

PRINCIPAL_INVESTIGATORGustavo Nader Marte

Latin American Cooperative Oncology Group

Outcome results